AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04282798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Music Intervention
Description: Participants will complete a series of questionnaires to identify participants' music preferences and participants' sensitivity to reward from musical engagement. The responses from the music preference questionnaires will be used to create a 1 hr playlist of songs by a member of the study team for the participant to be played daily for four weeks. After playlist is created and transmitted to MP3 device, participants will pick up the equipment and a compliance log will be given for the participant and participants' caregivers to confirm adherence to the protocol of daily listening. The platform will be Spotify, where the MP3 device given to participant at the start of the intervention will be preprogrammed with the participant's personal playlist on the platform. This trial is a supplementary treatment option for cognitive and neuropsychiatric assessments for AD, as such no alterations in the current treatment plans of any participant will be necessary.
Study NCT01566760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
Study NCT01566760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
Study NCT01566760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
Study NCT01566760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
Study NCT01566760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine fumarate
Description: one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
Study NCT00772525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: form: tablet~Route: oral
Study NCT00882401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol (Vitamin D)
Description: ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
Study NCT00882401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo at same dose schedule as ergocalciferol
Study NCT02389075 — intervention group
Intervention type: PROCEDURE
Intervention: Pinch biopsies
Description: Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
Study NCT02389075 — intervention group
Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy
Description: Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
Study NCT04205097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine + glycopyrate
Description: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
Study NCT04205097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 2-4 mg/kg
Study NCT01617148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
Study NCT02722525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo treadmill stress CMR
Study NCT02722525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete treadmill exercise
Study NCT02722525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Magnetic Resonance Imaging
Description: Undergo gadopentetate dimeglumine perfusion MRI
Study NCT02722525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistive lower extremity exercise
Study NCT02722525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spectroscopy
Description: Undergo skeletal muscle PMRS
Study NCT02722525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00728052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
Study NCT00728052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules will be administered orally with water.
Study NCT02901639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling
Study NCT01229397 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inflexal V
Description: vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
Study NCT01229397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V 0.5 mL administrated once only
Study NCT04115540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS penile nerve stimulation
Description: The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
Study NCT03127956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olumacostat Glasaretil Gel, 5.0%
Description: Gel containing Olumacostat Glasaretil
Study NCT02145507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SOLX (Investigational)
Description: SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
Study NCT02145507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AS-3 (Control)
Description: AS-3 solution is regulated as a drug but is not intended to provide a direct therapeutic benefit
Study NCT01960387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
Study NCT01960387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
Study NCT00702572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Description: This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which \<2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
Study NCT00702572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Description: Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
Study NCT00287079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
Study NCT00287079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: No treatment for 96 weeks
Study NCT02380820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airsoft Duo mattress
Description: A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
Study NCT02380820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softform Premier mattress (in static mode)
Description: A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
Study NCT02001025 — intervention group
Intervention type: DEVICE
Intervention: Absorb scaffold
Study NCT02001025 — intervention group
Intervention type: DEVICE
Intervention: Xience stent
Study NCT05350735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: SMS text reminders and medical card
Description: This study arm will assess compliance with anti-rabies vaccine regimen by participants in the presence of SMS text reminders as compared to without the SMS reminder.
Study NCT01973543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VY-AADC01
Description: Neurosurgical delivery of VY-AADC01 to the brain.
Study NCT04163718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: 800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
Study NCT03717454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
Study NCT03717454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug treatment
Description: The medication will continue if DA causes tumors to shrink.
Study NCT04212442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Living Program for Affordable Housing.
Description: Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches.
Study NCT06696807 — intervention group
Intervention type: DRUG
Intervention: glucocorticosteroids and/or intravenous immunoglobulin
Description: methylprednisolone: 20-200mg/day intravenous immunoglobulin: 5-20 g/day
Study NCT03136731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Celiac disease antibody screening
Description: Observational parameters
Study NCT01606254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Study NCT01127204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT-3TC-LPV/r twice a day
Description: AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
Study NCT00430651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
Study NCT03853798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
Study NCT00430651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
Study NCT03599401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~.
Study NCT03599401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~.
Study NCT00477581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study NCT01127204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC-3TC-EFV once a day
Description: ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
Study NCT00477581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning
Study NCT01740843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
Study NCT01740843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
Study NCT01740843 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)
Description: The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
Study NCT02594540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Peripheral Stimulation (GONDOLA)
Study NCT02594540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mechanical Peripheral Stimulation (GONDOLA)
Study NCT03960554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Inj 60 mg/ml
Description: Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
Study NCT03960554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
Study NCT00920231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: initial system
Description: The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
Study NCT00920231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: modified system
Description: The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
Study NCT02597634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST-0225
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Study NCT02597634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study NCT04744038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
Study NCT03812432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence cholecystocholangiography
Description: Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
Study NCT03120442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
Study NCT03120442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
Study NCT03120442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.25 mcg fo Fentanyl for anxiolysis
Study NCT03239964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
Study NCT03239964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical excision
Description: total extralesional surgical excision of the keloid is performed and minimal undermining
Study NCT02316912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX2417
Description: Randomised double blind parallel group ascending dose assessment
Study NCT00827307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
Study NCT02316912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised double blind parallel group ascending dose assessment
Study NCT00412490 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Written survey at 1 Month \& 6 Months post surgery.
Study NCT00412490 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: One-on-One meeting lasting about one hour, at 1 Month \& 6 Months post surgery.
Study NCT03614767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urodynamics
Description: Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
Study NCT03149393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi Weitong Granules
Description: Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
Study NCT03149393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate Tablets
Description: Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
Study NCT02122731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: 5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
Study NCT02791958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril 10 mg
Description: A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
Study NCT01408888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously
Study NCT01408888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally
Study NCT04122027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral oximeter
Description: Near infra-red spectroscopy, NIRS
Study NCT04025398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program
Description: Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
Study NCT04025398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)
Study NCT00201136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions to lower blood pressure for patients
Description: Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
Study NCT00201136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD CQI-type intervention
Description: CQI-type intervention for MD adherence to JNC guidelines for BP management
Study NCT03464058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 micronized capsules
Description: Oral capsules
Study NCT04554186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Description: Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound